Trial Profile
Various visual functions and vision-related quality of life in patients with macular edema secondary to retinal vein occlusion following intravitreal ranibizumab injection.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal vein occlusion
- Focus Therapeutic Use
- 26 Dec 2018 Planned number of patients changed from 70 to 46.
- 26 Dec 2018 Planned End Date changed from 28 Feb 2019 to 31 Dec 2019.
- 26 Jun 2017 Status changed from not yet recruiting to recruiting.